On Tuesday, H.C. Wainwright adjusted its stock price target for Century Therapeutics (NASDAQ:IPSC) shares, reducing it to $5 from the previous $9, while maintaining a Buy rating for the stock. The revision follows the company's announcement of updated Phase 1 data for its CNTY-101 treatment in CD19+ B cell lymphomas.
Century Therapeutics reported an 83% overall response rate, with 33% complete responses at the highest three-weekly 1B cell dose level in Schedule B. The data reflected outcomes from six patients with a median follow-up of 2.9 months. H.C. Wainwright noted the promising results but expressed a desire to observe the durability of these responses beyond six months.
The firm also highlighted that Century Therapeutics plans to escalate the dose to the three-weekly 3B cell level in Schedule B, anticipating potential improvements in efficacy. The focus is particularly on achieving a higher proportion of complete responses and sustaining them for over half a year.
Further details on the updated ELiPSE-1 dataset can be found in slides 17-22 of Century's corporate deck. The company anticipates providing additional clinical data by mid-2025, which could offer further insights into the treatment's performance and potential.
The reduced price target reflects a cautious yet optimistic outlook from H.C. Wainwright, balancing the impressive early results against the need for longer-term data to confirm the sustainability of the treatment's efficacy.
In other recent news, Century Therapeutics, a biotechnology firm, has announced significant changes to its executive team. The company has appointed Morgan Conn, Ph.D., as its new Chief Financial Officer, effective from October 14, 2024. Dr. Conn, previously the Chief Business Officer at Pharvaris, brings over two decades of experience in the biopharmaceutical industry.
Alongside this, Century Therapeutics has named Chad Cowan, Ph.D., as Chief Scientific Officer, starting his role on October 1, 2024. Cowan, a recognized figure in cell therapy, has held roles at CRISPR Therapeutics and Sana Biotechnology.
The company also shared that Hy Levitsky, M.D., currently serving as President of Research and Development, will transition to an advisory role. These recent developments are expected to enhance Century Therapeutics' strategic and scientific capabilities as it continues to progress its cell therapy platforms and clinical programs.
InvestingPro Insights
Century Therapeutics' financial metrics and market performance provide additional context to H.C. Wainwright's cautious optimism. The company's market capitalization stands at $112.67 million, with a price-to-book ratio of 0.51, suggesting the stock may be undervalued relative to its book value. This aligns with the analyst's maintained Buy rating despite the lowered price target.
InvestingPro Tips highlight that Century Therapeutics has a high revenue growth rate, which is evident in the impressive 678.79% quarterly revenue growth as of Q2 2024. This substantial growth could be attributed to the promising early results of CNTY-101 and other pipeline developments. However, it's important to note that the company is not yet profitable, with a negative P/E ratio and operating income.
The fair value estimate from analysts, as reported by InvestingPro, is $12 per share, significantly higher than the current trading price. This disparity underscores the potential upside that H.C. Wainwright sees in the stock, even with the reduced price target of $5.
For investors seeking a deeper understanding of Century Therapeutics' potential, InvestingPro offers 10 additional tips that could provide valuable insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.